var data={"title":"Cisatracurium: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cisatracurium: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5910?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cisatracurium-drug-information\" class=\"drug drug_general\">see &quot;Cisatracurium: Drug information&quot;</a> and <a href=\"topic.htm?path=cisatracurium-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cisatracurium: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152161\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Nimbex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152162\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cisatracurium Besylate Injection;</li>\n      <li>Cisatracurium Omega;</li>\n      <li>Nimbex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057396\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Neuromuscular Blocker Agent, Nondepolarizing</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Skeletal Muscle Relaxant, Paralytic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057390\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cisatracurium-drug-information\" class=\"drug drug_general\">see &quot;Cisatracurium: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dosing in obese patients should be calculated using ideal body weight (Playfor 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neuromuscular blockade:</b> IV (not to be used IM): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;2 years: 0.15 mg/kg over 5 to 10 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;2 years and Adolescents: 0.1 to 0.15 mg/kg over 5 to 10 seconds  (Martin 1999; Playfor 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: Infants, Children, and Adolescents: 1 to 4 <b>mcg</b>/kg/minute (0.06 to 0.24 mg/kg/<b>hour</b>); 3.9 &plusmn; 1.3 <b>mcg</b>/kg/minute (0.23 &plusmn; 0.08 mg/kg/<b>hour</b>) was the mean infusion rate needed to maintain neuromuscular blockade in 19 children (ages 3 months to 16 years) (Burmester 2005; Martin 1999; Playfor 2007); higher doses have been reported with prolonged infusions (Tobias 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Operating room administration: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Intubating dose:</i> 0.15 to 0.2 mg/kg as components of propofol/nitrous oxide/oxygen induction-intubation technique. <b>Note:</b> May produce generally good or excellent conditions for tracheal intubation in 1.5 to 2 minutes with clinically effective duration of action during propofol anesthesia of 55 to 61 minutes. Initial dose after succinylcholine for intubation: 0.1 mg/kg; maintenance dose: 0.03 mg/kg 40 to 60 minutes after initial dose, then at ~20-minute intervals based on clinical criteria. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Continuous infusion:</i> After an initial bolus, a diluted solution can be given by continuous infusion for maintenance of neuromuscular blockade during extended surgery; adjust the rate of administration according to the patient's response as determined by peripheral nerve stimulation. An initial infusion rate of 3 <b>mcg</b>/kg/minute (0.18 mg/kg/<b>hour</b>) may be required to rapidly counteract the spontaneous recovery of neuromuscular function; thereafter, a rate of 1 to 2 <b>mcg</b>/kg/minute (0.06 to 0.12 mg/kg/<b>hour</b>) should be adequate to maintain continuous neuromuscular block in the 89% to 99% range in most adult patients. Consider reduction of the infusion rate by 30% to 40% when administering during stable isoflurane, enflurane, sevoflurane, or desflurane anesthesia. Spontaneous recovery from neuromuscular blockade following discontinuation of infusion of cisatracurium may be expected to proceed at a rate comparable to that following single bolus administration. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intensive care unit administration:</b> Loading dose: 0.15 to 0.2 mg/kg; at initial signs of recovery from bolus dose, begin the infusion at a dose of 3 <b>mcg</b>/kg/minute (0.18 mg/kg/<b>hour</b>) and adjust rate accordingly (follow the principles for infusion in the operating room); dosage ranges of 0.5 to 10 <b>mcg</b>/kg/minute (0.03 to 0.6 mg/kg/<b>hour</b>) have been reported. If patient is allowed to recover from neuromuscular blockade, readministration of a bolus dose may be necessary to quickly reestablish neuromuscular block prior to reinstituting the infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling. Slower times to onset of complete neuromuscular block were observed in renal dysfunction patients; extending the interval between the administration of cisatracurium and intubation attempt may be required to achieve adequate intubation conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling. The time to onset of action was ~1 minute faster in patients with end-stage liver disease, but was not associated with clinically significant changes in recovery time.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152143\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nimbex: 20 mg/10 mL (10 mL) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nimbex: 10 mg/5 mL (5 mL); 200 mg/20 mL (20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/5 mL (5 mL); 200 mg/20 mL (20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/5 mL (5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152129\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057399\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Not for IM injection due to tissue irritation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rapid IV injection: Administer undiluted  over 5 to 10 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion: Further dilute in D<sub>5</sub>W or NS  and administer via infusion pump </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152158\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Refrigerate intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Use vials within 21 days upon removal from the refrigerator to room temperature of 25&deg;C  (77&deg;F). Per the manufacturer, dilutions of 0.1 mg/mL in 0.9% sodium chloride (NS), dextrose 5% in water (D<sub>5</sub>W), or D<sub>5</sub>NS are stable for up to 24 hours at room temperature or under refrigeration; dilutions of 0.1-0.2 mg/mL in D<sub>5</sub>LR are stable for up to 24 hours in the refrigerator.  <i>Additional stability data:</i> Dilutions of 0.1, 2, and 5 mg/mL in D<sub>5</sub>W or NS are stable in the refrigerator for up to 30 days; at room temperature (23&deg;C), dilutions of 0.1 and 2 mg/mL began exhibiting substantial drug loss between 7-14 days; dilutions of 5 mg/mL in D<sub>5</sub>W or NS are stable for up to 30 days at room temperature (23&deg;C) (Xu, 1998). Usual concentration: 0.1-0.4 mg/mL.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057398\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Adjunct to general anesthesia, to facilitate endotracheal intubation, and provide  skeletal muscle relaxation during surgery or mechanical ventilation (FDA approved in ages 1 month to 12 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152203\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nimbex may be confused with NovoLOG</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">United States Pharmacopeia (USP) 2006: The Interdisciplinary Safe Medication Use Expert Committee of the USP has recommended the following:</p>\n        <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">- Hospitals, clinics, and other practice sites should institute special safeguards in the storage, labeling, and use of these agents and should include these safeguards in staff orientation and competency training.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">- Healthcare professionals should be on high alert (especially vigilant) whenever a neuromuscular-blocking agent (NMBA) is stocked, ordered, prepared, or administered.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152200\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Effects are minimal and transient.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Bradycardia, bronchospasm, flushing, hypotension, muscle calcification (prolonged use), myopathy (acute quadriplegic syndrome; prolonged use), pruritus, skin rash</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152149\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cisatracurium besylate or any component of the formulation; use of the 10 mL multiple-dose vials in premature infants (formulation contains benzyl alcohol)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152133\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concern related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bradycardia: May be more common with cisatracurium than with other neuromuscular-blocking agents since it has no clinically-significant effects on heart rate to counteract the bradycardia produced by anesthetics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular cross-sensitivity: Cross-sensitivity with other neuromuscular-blocking agents may occur; use extreme caution in patients with previous anaphylactic reactions to other neuromuscular-blocking agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Burn injury: Resistance may occur in burn patients (&ge;20% of total body surface area), usually several days after the injury, and may persist for several months after wound healing (Han, 2009). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Conditions which may <i>antagonize</i> neuromuscular blockade: Respiratory alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, and muscle trauma may result in antagonism of neuromuscular blockade  (Greenberg, 2013; Miller, 2010; Murray, 2002; Naguib, 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Conditions which may <i>potentiate</i> neuromuscular blockade: Electrolyte abnormalities (eg, severe hypocalcemia, severe hypokalemia, hypermagnesemia), neuromuscular diseases, metabolic acidosis, metabolic alkalosis, respiratory acidosis, Eaton-Lambert syndrome and myasthenia gravis may result in potentiation of neuromuscular blockade (Greenberg, 2013; Miller, 2010; Naguib, 2002). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Therapeutic hypothermia: Hypothermia may slow Hoffmann elimination thereby prolonging the duration of activity (Greenberg, 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in the elderly, effects and duration are more variable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Immobilized patients: Resistance may occur in patients who are immobilized.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Maintenance of an adequate airway and respiratory support is critical. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Experienced personnel: Should be administered by adequately trained individuals familiar with its use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299048\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152137\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13160&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: Neuromuscular-Blocking Agents may diminish the therapeutic effect of Amifampridine. Amifampridine may diminish the therapeutic effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bacitracin (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capreomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clindamycin (Topical): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): Neuromuscular-Blocking Agents (Nondepolarizing) may enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin-Phenytoin: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalational Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Nasal): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Systemic): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lincosamide Antibiotics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<b> Exceptions: </b>Benzocaine; Benzydamine; Cocaine (Topical); Dibucaine; Dyclonine; Ethyl Chloride; Hexylresorcinol; Lidocaine (Ophthalmic); Lidocaine (Topical); Pramoxine; Proparacaine; Tetracaine (Ophthalmic); Tetracaine (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents. Specifically, anaphylaxis has been reported.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Polymyxin B: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Procainamide: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spironolactone: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimebutine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152139\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13494843\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057395\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Muscle twitch response to peripheral nerve stimulation, heart rate, blood pressure, assisted ventilation status </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152132\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Blocks neural transmission at the myoneural junction by binding with cholinergic receptor sites</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152148\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: IV: 2-3 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: 3-5 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Dose dependent, 35 to 45 minutes after a single 0.1 mg/kg dose; recovery begins in 20-35 minutes when anesthesia is balanced; recovery is attained in 90% of patients in 25-93 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>dss</sub>: 145 mL/kg (21% larger V<sub>dss</sub> when receiving inhalational anesthetics)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Not studied due to rapid degradation at physiologic pH</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Undergoes rapid nonenzymatic degradation in the bloodstream (Hofmann elimination) to laudanosine and inactive metabolites; laudanosine may cause CNS stimulation (association not established in humans) and has less accumulation with prolonged use than atracurium due to lower requirements for clinical effect</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 22-29 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (95%; &lt;10% as unchanged drug); feces (4%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance: Children: 5.89 mL/kg/minute; Adults: 4.57 mL/kg/minute </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15597926\" class=\"nested sp-pop-child-nested drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Minor differences in pharmacokinetic/pharmacodynamic parameters in children resulted in a faster time to onset and a shorter duration of neuromuscular block.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323070\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cisatracurium Besylate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/5 mL (5 mL): $16.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/10 mL (10 mL): $27.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/20 mL (20 mL): $324.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nimbex Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/5 mL (5 mL): $18.81</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/10 mL (10 mL): $33.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/20 mL (20 mL): $356.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Cisatracurium Besylate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/5 mL (5 mL): $29.14</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152152\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Nimbex (AE, AR, AT, AU, BB, BE, BH, BM, BS, BZ, CH, CL, CN, CY, CZ, DE, DK, EC, EG, ES, ET, FI, FR, GB, GR, GT, GY, HK, HN, HU, IE, IL, IQ, IR, IT, JM, JO, KR, KW, LB, LT, LU, LV, LY, MT, MX, MY, NL, NO, OM, PA, PE, PL, PR, PT, QA, RO, RU, SA, SE, SI, SR, SV, SY, TH, TR, TT, TW, YE, ZW);</li>\n      <li>Nimbium (BR, CO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisatracurium-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisatracurium-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burmester M and Mok Q, &quot;Randomised Controlled Trial Comparing Cisatracurium and Vecuronium Infusions in a Paediatric Intensive Care Unit,&quot; <i>Intensive Care Med</i>, 2005, 31(5):686-92. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisatracurium-pediatric-drug-information/abstract-text/15815895/pubmed\" target=\"_blank\" id=\"15815895\">15815895</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisatracurium-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenberg SB and Vender J, &ldquo;The Use of Neuromuscular Blocking Agents in the ICU: Where Are We Now?&rdquo; <i>Crit Care Med</i>, 2013, 41(5):1332-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisatracurium-pediatric-drug-information/abstract-text/23591211/pubmed\" target=\"_blank\" id=\"23591211\">23591211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Han TH, Martyn JAJ. Onset and effectiveness of rocuronium for rapid onset of paralysis in patients with major burns: priming or large bolus. <i>Br J Anaesth</i>. 2009;102(1):55-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisatracurium-pediatric-drug-information/abstract-text/19029093/pubmed\" target=\"_blank\" id=\"19029093\">19029093</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin LD, Bratton SL, and O'Rourke PP, &ldquo;Clinical Uses and Controversies of Neuromuscular Blocking Agents in Infants and Children,&rdquo; <i>Crit Care Med</i>, 1999, 27(7):1358-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisatracurium-pediatric-drug-information/abstract-text/ 10446832 /pubmed\" target=\"_blank\" id=\" 10446832 \"> 10446832 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nimbex injection (cisatracurium) [prescribing information]. Lake Forest, IL: Hospira, Inc; January 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Playfor S, Jenkins I, Boyles C, et al, &quot;Consensus Guidelines for Sustained Neuromuscular Blockade in Critically Ill Children,&quot; <i>Paediatr Anaesth</i>, 2007, 17(9):881-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisatracurium-pediatric-drug-information/abstract-text/17683408/pubmed\" target=\"_blank\" id=\"17683408\">17683408</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tobias JD. A prospective evaluation of the continuous infusion of cis-atracurium for neuromuscular blockade in the pediatric intensive care unit patient: efficacy and dosage requirements. <i>Am J Ther</i>. 1997;4(9-10):287-290. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisatracurium-pediatric-drug-information/abstract-text/10423621 /pubmed\" target=\"_blank\" id=\"10423621 \">10423621 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Xu QA, Zhang YP, Trissel LA, et al, &quot;Stability of Cisatracurium Besylate in Vials, Syringes, and Infusion Admixtures,&quot; <i>Am J Health Syst Pharm</i>, 1998, 55(10):1037-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisatracurium-pediatric-drug-information/abstract-text/9606456/pubmed\" target=\"_blank\" id=\"9606456\">9606456</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13160 Version 108.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F152161\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F152162\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1057396\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1057390\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F152143\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F152129\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1057399\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F152158\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1057398\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F152203\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F152200\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F152149\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F152133\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299048\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F152137\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F152139\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13494843\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1057395\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F152132\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F152148\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Pediatric Considerations\" href=\"#F15597926\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323070\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F152152\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13160|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cisatracurium-drug-information\" class=\"drug drug_general\">Cisatracurium: Drug information</a></li><li><a href=\"topic.htm?path=cisatracurium-patient-drug-information\" class=\"drug drug_patient\">Cisatracurium: Patient drug information</a></li></ul></div></div>","javascript":null}